Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management
Strategic Profile
The company designs and commercializes continuous glucose monitoring systems that serve as an alternative to traditional blood glucose meters and is evolving its CGM systems to provide integration with insulin pumps for automatic insulin delivery. Growth is driven by higher sensor volumes, the Stelo rollout (for prediabetes and Type 2 patients), and further international expansion.
Cyborg Score Rationale
FY 2025 revenue reached approximately $4.662 billion, an increase of 16% over 2024. The company demonstrated a net margin of 17.94% and a return on equity of 32.12%. Operating margins expanded by 8.7 percentage points over five years and increased by 3.1 percentage points on a two-year basis, showing strong operational leverage.
Top Insights
Q4 2025 results beat expectations with $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY growth).
2026 revenue guidance of $5.16-$5.25 billion tied to sensor volumes, Stelo rollout, and international expansion.
Received FDA clearance for Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer.
Launched G7 15 Day system at end of 2025; in January 2026, fully launched across all channels (pharmacy and DME suppliers) in the U.S.
Named Competitors
Eversense — Implantable continuous glucose monitoring system
t:slim X2 — Insulin pump with integrated CGM compatibility